MedImmune Signs Cancer Pact with Immunocore - - BioPharm International

ADVERTISEMENT

MedImmune Signs Cancer Pact with Immunocore


p>MedImmune, the biologics R&D arm of AstraZeneca, has entered into a cancer research collaboration with UK-based biotech company Immunocore. Under the terms of the licensing agreement, both companies will conduct research to develop novel cancer therapies using Immunocore’s Immune Mobilising Monoclonal T-Cell Receptor Against Cancer (ImmTAC) technology. The platform harnesses the patient’s immune system by directing T cells to target and destroy cancerous cells without damaging healthy cells. Immunocore and MedImmune will work together to generate ImmTACs against selected cancer targets.

AstraZeneca and MedImmune will have rights to further develop and commercialize ImmTAC products. Immunocore will receive an upfront payment of $20 million per program and is eligible to receive up to $300 million in development and commercial milestone payments for each target program and significant tiered royalties from successful programs.

Source: AstraZeneca

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Lilly to Acquire Novartis Animal Health
April 22, 2014
Novartis and GSK Trade Assets
April 22, 2014
Mallinckrodt to Acquire Questcor Pharmaceuticals
April 16, 2014
EMA Warns of Falsified Herceptin Vials
April 16, 2014
American CryoStem and Rutgers University File Joint Patent on Stem Cell Platform
April 11, 2014
Author Guidelines

Click here